Fate Therapeutics (FATE) Operating Income (2012 - 2026)

Fate Therapeutics has reported Operating Income for 15 years, with the latest figure at -$33.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 20.06% year-over-year to -$33.0 million; the trailing twelve-month figure through Mar 2026 stood at -$139.4 million (up 30.46% YoY), and the FY2025 full-year result was -$147.7 million, up 29.76% from the prior year.
• Operating Income for Q1 2026 stood at -$33.0 million, up from -$34.7 million in the prior quarter.
• The five-year high for Operating Income was -$28.6 million in Q1 2023, with the low at -$86.4 million in Q3 2022.
• Historically, Operating Income has averaged -$52.3 million across 5 years, with a median of -$51.1 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Income soared 61.6% — and 2024, when it tumbled 78.61%.
• Fate Therapeutics' Operating Income stood at -$64.4 million in 2022, then rose by 25.37% to -$48.1 million in 2023, then fell by 28.44% to -$61.7 million in 2024, then jumped by 43.77% to -$34.7 million in 2025, then rose by 4.96% to -$33.0 million in 2026.
• The last three Operating Income figures came in at -$33.0 million (Q1 2026), -$34.7 million (Q4 2025), and -$34.7 million (Q3 2025), per Business Quant data.